NCT04006054

Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury

Cerebral Protection of Dexmedetomidine Against Paroxysmal Sympathetic Overexcited in Patients With Traumatic Brain Injury

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.

Detailed description

Paroxysmal sympathetic hyperactivity (PSH) is a syndrome typically recognized in patients suffering from traumatic brain injury, characterized by paroxysmal increases in sympathetic activity such as elevated heart rate, increased blood pressure and respiratory rate, high temperature, excessive sweating and abnormal motor (posturing) activity. This prospective study will include patients with traumatic brain injury,who will be divided into two groups, evaluated by the Paroxysmal Sympathetic Hyperactivity-Assessment Measure (PSH-AM). Patients will also be evaluated with head CT. The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.

Conditions

• Traumatic Brain Injury

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
DRUG	Midazolam	When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .

Timeline

• Start date: 2019-06-06
• Primary completion: 2021-06-30
• Completion: 2021-12-30
• First posted: 2019-07-02
• Last updated: 2019-07-02

Locations

1 site across 1 country: China